alexa Splice Modulation Therapy For Inherited Retinal Diseases
ISSN: 2157-7412

Journal of Genetic Syndromes & Gene Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd World Congress on Rare Diseases and Orphan Drugs
June 29-30, 2017 London, UK

Rob W J Collin
Radboud University Medical Center, The Netherlands
ScientificTracks Abstracts: J Genet Syndr Gene Ther
DOI: 10.4172/2157-7412-C1-012
Abstract
Statement of the Problem: Inherited retinal diseases (IRDs) are characterized by severe and progressive visual impairment, often leading to complete blindness. IRDs display a tremendous genetic and clinical heterogeneity, and to date, no effective treatment exists. A significant fraction of the genetic defects underlying IRD affect pre-mRNA splicing of the corresponding gene. We therefore decided to employ antisense oligonucleotides (AONs) to develop splice modulation therapy for specific genetic subtypes of IRD. AONs are small and versatile DNA/RNA molecules that bind complementary to their target pre-mRNA molecule and are able to redirect pre-mRNA splicing. Methodology & Theoretical Orientation: Fibroblast cell lines derived from patients harboring mutations that affect pre-mRNA splicing were generated and cultured in the presence of AONs that are specifically designed to correct pre-mRNA splicing. In some cases, fibroblasts were first reprogrammed to induced pluripotent stem cells that were subsequently differentiated to photoreceptor precursor cells, and then treated with AONs. RT-PCR analysis was performed to study the efficacy of AON treatment, and for some cell lines, Western blot analysis or immunocytochemical analysis was performed to determine the effects at the protein and cellular level. Findings: AON administration to patient-derived fibroblast cells harboring a recurrent splice mutation underlying severe early-onset IRD, i.e. c.2991+1655A>G in CEP290, resulted in full restoration of CEP290 pre-mRNA splicing, a significant increase in CEP290 protein levels, and rescue of a ciliary defect. In addition, AON delivery to patient cells with splice mutations in ABCA4 resulted in correction of the splice defects. Studies targeting additional mutations affecting pre-mRNA splicing that underlie IRD are currently ongoing. Conclusion & Significance: Splice modulation therapies represent a promising and attractive strategy for the future treatment of specific genetic subtypes of IRD.
Biography

Rob W J Collin is an Associate Professor at the Department of Human Genetics, at the Radboud University Medical Center in Nijmegen, The Netherlands, and is affiliated to the Donders Institute for Brain, Cognition and Behaviour. During his Post-doc, he was involved in the identification of several novel genes underlying inherited hearing impairment, and inherited retinal diseases. From 2010, he switched his research focus towards the development of Molecular Therapies for Inherited Eye Disorders, in particular those that involve the modulation of pre-mRNA splicing. In 2010, he worked in the lab of Prof. Dr. Jean Bennett, a pioneer in the development of retinal gene therapy. He was awarded with a prestigious VENI Award from the Dutch Organization of Scientific Research (2010), an Individual Investigator Award from the Foundation Fighting Blindness (2012), and recently received the IJMS Young Investigator Award (2017).

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords